A detailed history of Nisa Investment Advisors, LLC transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 308 shares of MCRB stock, worth $283. This represents 0.0% of its overall portfolio holdings.

Number of Shares
308
Previous 308 -0.0%
Holding current value
$283
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

BUY
$0.56 - $1.19 $112 - $238
200 Added 185.19%
308 $0
Q1 2024

May 01, 2024

BUY
$0.75 - $1.56 $81 - $168
108 New
108 $0
Q3 2023

Nov 02, 2023

SELL
$2.33 - $5.07 $118 - $258
-51 Reduced 1.91%
2,620 $6,000
Q2 2023

Aug 11, 2023

BUY
$4.67 - $6.55 $9,718 - $13,630
2,081 Added 352.71%
2,671 $12,000
Q1 2022

Apr 29, 2022

SELL
$6.3 - $8.84 $33,390 - $46,852
-5,300 Reduced 89.98%
590 $4,000
Q4 2021

Feb 03, 2022

BUY
$6.02 - $11.43 $31,905 - $60,579
5,300 Added 898.31%
5,890 $49,000
Q3 2021

Oct 18, 2021

SELL
$5.46 - $22.6 $18,018 - $74,580
-3,300 Reduced 84.83%
590 $4,000
Q2 2021

Aug 06, 2021

BUY
$18.46 - $24.36 $60,918 - $80,388
3,300 Added 559.32%
3,890 $93,000
Q1 2021

Apr 26, 2021

SELL
$17.66 - $28.92 $34,437 - $56,394
-1,950 Reduced 76.77%
590 $12,000
Q4 2020

Jan 25, 2021

SELL
$23.25 - $37.73 $6,975 - $11,318
-300 Reduced 10.56%
2,540 $62,000
Q3 2020

Oct 20, 2020

BUY
$3.74 - $28.74 $6,919 - $53,169
1,850 Added 186.87%
2,840 $80,000
Q1 2020

Apr 17, 2020

BUY
$2.64 - $3.82 $2,613 - $3,781
990 New
990 $4,000
Q4 2017

Jan 12, 2018

SELL
$9.15 - $12.64 $38,430 - $53,088
-4,200 Closed
0 $0
Q3 2017

Oct 13, 2017

BUY
$12.81 - $16.85 $53,802 - $70,770
4,200
4,200 $67,000

Others Institutions Holding MCRB

About Seres Therapeutics, Inc.


  • Ticker MCRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,072,000
  • Market Cap $114M
  • Description
  • Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...
More about MCRB
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.